Urologic Oncology-Seminars and Original Investigations

Papers
(The TQCC of Urologic Oncology-Seminars and Original Investigations is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Editorial Board51
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors46
Interpreting nephrometry scores with three-dimensional virtual modelling for better planning of robotic partial nephrectomy and predicting complications43
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study43
An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique32
Differences in cancer presentation, treatment, and mortality between rural and urban patients diagnosed with kidney cancer in the United States29
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out29
Introduction to the seminar on “the impact of complications on surgeons”27
Characteristics, trends, and management of Penile cancer in the United States: A population-based study27
Complications and Surgeon Health: Resources for individuals and institutions26
Confronting the inevitable: When a urologist feels like a second victim26
The emotional toll of surgical complications in the early career25
Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)25
Durability of response of UGN-101: Longitudinal follow up of multicenter study25
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey24
Concordance of surgical treatment selection with the AUA guidelines for localized renal masses23
Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure23
Editorial Board22
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials22
Integrated care among patients with kidney or urinary bladder cancer: An NCI patterns-of-care analysis22
The role of intravesical chemotherapy following nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis22
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset22
TRANSCRIPTIONAL ANALYSIS OF BLADDER CANCER HISTOLOGIC SUBTYPES REVEALS NOVEL DRUG TARGET HETEROGENEITY21
QUALITY OF LIFE, DECISIONAL REGRET, AND FEAR OF RECURRENCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER MANAGED WITH SURVEILLANCE AFTER CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY21
UTILITY OF RESCUE BACILLUS CALMETTE-GUERIN THERAPY IN TREATMENT OF BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER21
PHASE 1B/2 STUDY OF COMBINATION 177LU GIRENTUXIMAB PLUS CABOZANTINIB AND NIVOLUMAB IN TREATMENT NAIVE PATIENTS WITH ADVANCED CLEAR CELL RCC21
SAME DAY DISCHARGE OF OPEN AND MINIMALLY INVASIVE RENAL SURGERY IS FEASIBLE AND SAFE21
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES21
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA20
COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB OR COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB FOR BACILLUS CALMETTE-GUÉRIN (BCG)–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER (NMIBC): COHORT C OF PHAS20
REPEATABILITY OF CANCER MUTATION DETECTION IN URINE LIQUID BIOPSY: MORE SAMPLES ARE BETTER20
RETHINKING CHEMOTHERAPY TIMING IN STAGE II NSGCT: BALANCING SURVIVAL AND MINIMIZING TOXICITY20
INNOVATIVE DIAGNOSTIC APPROACHES: SERUM PROTEIN MARKERS IN RENAL CELL CARCINOMA19
SMOKING AND EXERCISE ARE INDEPENDENTLY ASSOCIATED WITH MENTAL HEALTH IN PROSTATE CANCER19
PSMA EXPRESSION IS INVERSELY ASSOCIATED WITH METASTATIC PROGRESSION FOLLOWING SURGERY IN CLINICALLY LOCALIZED RENAL CELL CARCINOMA19
DETERMINING LONG-TERM PROSTATE CANCER OUTCOMES FOR ACTIVE SURVEILLANCE PATIENTS WITHOUT EARLY DISEASE PROGRESSION: IMPLICATIONS FOR SLOWING OR STOPPING SURVEILLANCE18
IDENTIFYING FACTORS ASSOCIATED WITH PROSTATE CANCER RECURRENCE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) TREATMENT: IMPLICATIONS FOR FUTURE PATIENT SELECTION18
SURVIVAL PATTERNS AMONG CLINICALLY NODE POSITIVE PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY18
EVALUATION OF RESPONSE TO 177LU-PSMA-617 BY SITE SPECIFIC DISEASE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER18
NEUTROPHIL AND TUMOR-INFILTRATING LYMPHOCYTE COUNT ARE ASSOCIATED WITH BLADDER CANCER STAGE AND TREATMENT RESPONSE IN BCG-TREATED MICE MODELS18
HEALTH-RELATED QUALITY OF LIFE IN OVERWEIGHT/OBESE MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER ACTIVE LIFESTYLE STUDY RANDOMIZED CONTROLLED TRIAL17
WHOLE-BODY MAGNETIC RESONANCE IMAGING FOR STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER17
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY17
IDENTIFICATION OF OVER 40 NOVEL TESTICULAR GERM CELL TUMOR SUSCEPTIBILITY LOCI17
TUMOR CHARACTERISTICS ASSOCIATED WITH PREOPERATIVELY DETECTABLE TUMOR-INFORMED CIRCULATING TUMOR DNA IN PATIENTS WITH RENAL MASSES SUSPICIOUS FOR RCC17
OUTCOMES FOR SECONDARY MUSCLE INVASIVE BLADDER CANCER: HOW FAR HAVE WE PROGRESSED?16
PATIENT-REPORTED FUNCTIONAL DECLINE FOLLOWING RADICAL PROSTATECTOMY (RP) OR EXTERNAL BEAM RADIATION WITH ANDROGEN DEPRIVATION THERAPY (EBRT W/ ADT) FOR UNFAVORABLE-RISK PROSTATE CANCER16
COMPARING EFFICACY OF INTRAVESICAL GEMCITABINE/DOCETAXEL AND BCG IN TREATING VERY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AS DEFINED BY THE EUROPEAN ASSOCIATION OF UROLOGY (EAU)16
TREATMENT DECISION-MAKING AND POST-TREATMENT REGRET AMONG PROSTATE CANCER PATIENTS AT A MULTIDISCIPLINARY, EQUAL ACCESS MILITARY CLINICAL CARE CENTER16
UROTHELIAL CARCINOMA OF THE PROSTATE AND INTRAVESICAL THERAPY: A CAUTIONARY TALE16
MEASURING THE EFFECTS OF NEIGHBORHOOD SOCIOECONOMIC DEPRIVATION AND RACE ON SURVIVAL IN UROTHELIAL BLADDER CANCER USING A STATE-SPECIFIC COMMUNITY LEVEL MEASURE16
A PHASE 1 DOSE-ESCALATION STUDY OF UGN-301 (ZALIFRELIMAB) AS MONOTHERAPY AND IN COMBINATION WITH OTHER AGENTS IN PATIENTS WITH RECURRENT NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)16
TSC1 MUTANT BLADDER CANCER REQUIRES TFE3, IDENTIFYING A POTENTIAL THERAPEUTIC VULNERABILITY16
OUTCOMES OF PATIENTS TREATED WITH ADDITIONAL BCG FOLLOWING A BCG UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER DIAGNOSIS15
EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG UTUC): ENLIGHTED PHASE 3 STUDY15
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study14
The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer14
CORRELATIVE SCIENCE FROM A PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)14
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients14
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions14
Acute kidney injury as an independent predicting factor for stage 3 or higher chronic kidney disease after nephrectomy14
WHO DOES OPEN SURGERY NOWADAYS? SURGEON FACTORS ASSOSCIATED WITH OPEN ONCOLOGIC SURGERY AMONG AMERICAN BOARD OF UROLOGY EXAMINEES14
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy14
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis14
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers14
Inverted urethral flap reconstruction after partial penectomy: Long-term oncological and functional outcomes14
CAN GENOMIC CLASSIFIERS IN BIOPSY CORES WITH GRADE GROUP 1 CANCER PREDICT HIGHER-GRADE DISEASE ELSEWHERE IN THE PROSTATE? RESULTS FROM THE MIAMI ACTIVE SURVEILLANCE TRIAL14
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment14
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis13
“Advancing bladder preservation: Biomarkers, decision-making, and therapy”13
PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 5-YEAR FOLLOW UP13
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer13
Age related differences in primary testicular lymphoma: A population based cohort study13
Radical cystectomy and urinary diversion outcomes in patients with single vs. double renal unit: A 2:1 matched-pair analysis13
Cover 3 - GF 39713
Cover 2 - Masthead13
Letter to the Editor, Re: Reitblat et al. 202113
Regional differences in upper tract urothelial carcinoma patients across the United States13
Characterization of perioperative androgen profiles in men with bladder cancer undergoing radical cystectomy13
Michael Droller: Teacher, mentor, confidant and friend12
Table of Contents12
Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis12
Festschrift essay to celebrate Dr. Michael Droller12
Table of Contents12
Comparison of aggressiveness in central versus peripheral T1a clear-cell renal cell carcinoma12
Thank You12
Multicenter study of active surveillance for small renal masses: Real world practice pattern12
Tribute to Michael Droller MD12
Tribute to Michael Droller12
Clock gene NR1D1 might be a novel target for the treatment of bladder cancer12
Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates12
Subsequent primary urogenital cancers among childhood and adolescent cancer survivors in the United States11
Pathologic fracture in metastatic kidney cancer: Identifying widening disparities and opportunity for quality improvement11
Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy11
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel11
Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions11
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction11
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome11
2021 Joseph A. Smith, Jr. Mentorship lecture: Discovery11
Cover 2 - Masthead11
Germline genetics in prostate cancer: Amidst a paradigm shift11
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy11
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma11
A new index (A/G) associated with early complications of radical cystectomy and intestinal urinary diversion11
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis10
Clinical characteristics of renal cell carcinoma in patients under the age of 4010
Table of Contents10
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma10
SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence10
Reply to Khurshid R. Ghani's letter to editor regarding the article “Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter evaluation of practice patterns and10
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors10
Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?10
The early impact of medicaid expansion on urologic malignancies in the United States10
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?10
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy10
Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease10
Cover 2 - Masthead10
Age of menarche and primary bladder cancer risk: A meta-analysis and systematic review10
Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration10
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites10
Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: A systematic review and meta-analysis10
hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review10
Editorial Board10
Cover 2 - Masthead10
Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term o10
Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefi10
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy10
Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years10
Higher prevalence of benign tumors in men with testicular tumors and history of treated cryptorchidism10
Table of Contents9
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database9
Validation of Epstein criteria and development of a nomogram for active surveillance in a contemporary Chinese population9
Editorial Board9
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial9
Is YouTube a good resource for patients to better understand kidney cancer?9
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma9
The pathway of isolated seminal vesicle invasion has a different impact on biochemical recurrence after radical prostatectomy and pelvic lymphadenectomy9
Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications9
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor9
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study9
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer9
The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?9
Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup9
Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan9
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma9
Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria9
Impact of heavy metals, oxidative stress, expression of VHL, and antioxidant genes in the pathogenesis of renal cell carcinoma9
Inguinal lymph node dissection in the era of minimally invasive surgical technology9
EXAMINING SURVIVAL OUTCOMES AND MOLECULAR DRIVERS OF TESTIS CANCER IN HISPANIC MEN8
Assessing pentafecta achievement after robot-assisted radical cystectomy and its association with surgical experience: Results from a high-volume institution8
Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies8
Cover 2 - Masthead8
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study8
A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers8
Functional outcomes after prostate cancer treatment: A comparison between single and multiple modalities8
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE8
MOLECULAR CORRELATES WITH PSMA EXPRESSION IN PRIMARY PROSTATE CANCER8
CHARACTERIZATION OF NAV1.7 EXPRESSION IN PROSTATIC NERVES FOLLOWING RADICAL PROSTATECTOMY8
UPDATED EFFICACY AND SAFETY OF ORAL ERDAFITINIB IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE, HIGH-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2 COHORT 28
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER8
Is primary retroperitoneal lymph node dissection the way forward for patients with testicular seminoma and limited retroperitoneal metastases?8
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer8
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis8
Table of Contents8
Cumulative smoking exposure impacts oncologic outcomes of upper tract urothelial carcinoma8
Table of Contents8
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer8
ULTRASOUND ECHOGENICITY CAN RISK STRATIFY LESIONS ON MP-MRI FOR CLINICALLY SIGNIFICANT PROSTATE CANCER8
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES8
MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS8
NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES8
C-REACTIVE PROTEIN KINETICS ARE ASSOCIATED WITH PROGRESSION AND SURVIVAL IN SURGICALLY TREATED RENAL CELL CARCINOMA PATIENTS8
Telemedicine in urologic oncology care: Will telemedicine exacerbate disparities?8
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs8
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients8
The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer8
SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to evaluate clinical net benefit8
Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer8
Should grade group 1 prostate cancer be reclassified as “non-cancer”? A pathology community perspective8
COMPARISON OF PARTIAL GLAND CRYOABLATION AND ROBOTIC RADICAL PROSTATECTOMY: A PROPENSITY-SCORE MATCHED ANALYSIS8
UNRAVELING THE WEB OF FRAILTY: A NOVEL APPROACH TO FRAILTY USING A COMPREHENSIVE GERIATRIC ASSESSMENT-DERIVED SPIDER PLOT8
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION8
Causal relationship between bladder cancer and gut microbiota contributes to the gut-bladder axis: A two-sample Mendelian randomization study7
The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer7
PROFILING THE TUMOR IMMUNE MICROENVIRONMENT OF PAPILLARY RENAL CELL CARCINOMA7
A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)7
SQUAMOUS CELL CARCINOMA OF THE RENAL PELVIS: TREATMENT IMPACT AND SURVIVAL OUTCOMES IN THE NATIONAL CANCER DATABASE7
IS PATHOLOGICAL UPSTAGING TO T3A RENAL CELL CARCINOMA ASSOCIATED WITH A SIMILAR PROGNOSIS TO NON-UPSTAGED PATHOLOGIC T3A DISEASE? A MULTICENTER ANALYSIS7
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER7
THE PROGNOSTIC SIGNIFICANCE AND GENETIC PROFILE OF PROSTATE CANCER WITH EXPANSILE CRIBRIFORM GLEASON PATTERN 47
THE ROLE OF OVARIAN PRESERVATION IN MAINTAINING SEXUAL FUNCTION AFTER RADICAL CYSTECTOMY7
COMPARISON OF APIXABAN VERSUS ENOXAPARIN FOR EXTENDED PROPHYLAXIS AFTER RADICAL CYSTECTOMY (CARE)7
High-intensity end-of-life care among Medicare beneficiaries with bladder cancer7
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies7
ALTERATIONS IN THE GUT MICROBIOME ARE ASSOCIATED WITH THE DEVELOPMENT OF POSTOPERATIVE ILEUS AND INFECTIONS IN PATIENTS UNDERGOING CYSTECTOMY AND URINARY DIVERSION7
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY7
GROWTH KINETICS OF VENOUS TUMOR THROMBUS IN PATIENTS WITH RENAL CELL CARCINOMA7
IMMUNOTHERAPY UTILIZATION PATTERNS IN METASTATIC BLADDER CANCER: ASSESSING INSURANCE STATUS AS A MODIFIABLE FACTOR ASSOCIATED WITH FAILURE TO RECEIVE NOVEL THERAPIES7
MAYO ADHESIVE PROBABILITY SCORE IS ASSOCIATED WITH WORSE OVERALL SURVIVAL IN PATIENTS UNDERGOING SURGERY FOR CLINICAL STAGE T1 RENAL CELL CARCINOMA7
INTER-RATER RELIABILITY AND DIAGNOSTIC ACCURACY OF PI-RADS SCORING BETWEEN ACADEMIC AND COMMUNITY CARE NETWORKS: HOW WIDE IS THE GAP7
CLINICAL, MOLECULAR AND IMMUNOHISTOCHEMICAL PROFILES OF CLEAR CELL ADENOCARCINOMA OF THE URINARY TRACT7
DECOMPRESSION OR NOT: THE ONGOING CHALLENGE OF MALIGNANT HYDRONEPHROSIS7
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST7
The assessment of bladder cancer resectability with bimanual palpation: A prospective study in laparoscopy and open cystectomy patients7
Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist7
The use of nephron-sparing intervention does not appear to be compromised after a period of active surveillance for patients with cT1 renal masses7
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer7
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”7
GERMLINE VARIANTS LINKED TO OVARIAN AND BLADDER CANCER IN FEMALES: IS OVARY SPARING RADICAL CYSTECTOMY AN OPTION?7
SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]7
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors7
DISPARITIES IN UTILIZATION OF GENETIC EVALUATION IN PATIENTS WITH KIDNEY CANCER WHO MEET GUIDELINES FOR GENETIC REFERRAL7
THE RELATIONSHIP BETWEEN SMOKING STATUS AND POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS7
INCIDENTAL CARCINOMA AFTER SINGLE-PORT TRANSVESICAL ROBOT-ASSISTED SIMPLE PROSTATECTOMY7
PSMA PET/CT-DETECTED MESORECTAL NODAL METASTASIS IN BIOCHEMICALLY RECURRENT PROSTATE CANCER PATIENTS7
LEGEND, A PHASE 1/2 STUDY OF DETALIMOGENE VORAPLASMID (EG-70) INTRAVESICAL MONOTHERAPY DEMONSTRATED CLINICAL RESPONSES IN BCG-UNRESPONSIVE NMIBC PATIENTS WITH CIS7
The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance7
Comparing direct medical care costs of patients with bladder cancer who received an ileal conduit vs. neobladder in the year following cystectomy7
COVID-19 vaccination: Prioritization of at risk groups6
Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androge6
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study6
Change in telomere length and cardiovascular risk factors in testicular cancer survivors6
Table of Contents6
The natural history of muscle-invasive bladder cancer in geriatric patients undergoing transurethral resection only: Outcome and cost6
How does a prebiopsy mri approach for prostate cancer diagnosis affect prostatectomy upgrade rates?6
Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients6
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study6
68Ga-PSMA PET/CT and 18F-FDG PET/CT in the diagnosis of prostatic ductal cancer6
Bladder cancer risk stratification using a urinary mRNA biomarker panel – A path towards cystoscopy triaging6
The centralization of bladder cancer care and its implications for patient travel distance6
Partial nephrectomy should be classified as an inpatient procedure: Results from a statewide quality improvement collaborative6
Engaging disparities in prostate cancer: Piloting an interactive, virtual workshop to educate providers on shared decision-making for underserved populations6
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns6
Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses6
Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database6
Guideline discordant care in patients with metastatic germ cell tumors6
Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation6
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors6
A noninvasive comprehensive model based on medium sample size had good diagnostic performance in distinguishing renal fat-poor angiomyolipoma from homogeneous clear cell renal cell carcinoma6
Randomized trials of PSA screening6
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma6
Editorial Board6
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy6
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-36
Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score6
Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: A follow up study6
Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection6
Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes6
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis6
Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs6
0.10010600090027